Chimerix Inc
(STU:CXF)
€
3.03
0.21 (7.45%)
Market Cap: 298.58 Mil
Enterprise Value: 168.48 Mil
PE Ratio: 0
PB Ratio: 2.29
GF Score: 51/100 Chimerix Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023 / 07:30PM GMT
Release Date Price:
€1.33
(-3.97%)
Maury Raycroft
Jefferies - Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the Biotech Analysts at Jefferies. I'm happy to introduce our guest today, Mike Sherman, President and CEO of Chimerix, and Mike Andriole, the CFO. This is going to be a fireside chat format. Thanks so much for joining us today.
Mike Sherman
Chimerix, Inc. - CEO
Thanks for having us, Maury.
Mike Andriole
Chimerix, Inc. - CFO and Chief Business Officer
Thanks, Maury.
Maury Raycroft
Jefferies - Analyst
And maybe to start off if -- for those who are new to the story, if you want to provide a one minute intro to Chimerix.
Mike Sherman
Chimerix, Inc. - CEO
Sure. Our most advanced program, ONC201 or dordaviprone is being developed in H3 K27M, so a genetically mutated patient population within glioma. The Phase 2 trial, which is the basis for advancing to that gave us a really good insight into definitive durable responses in the relapse
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot